ATE154758T1 - Levobupivacain nützlich zur behandlung von chronischen schmerzen - Google Patents

Levobupivacain nützlich zur behandlung von chronischen schmerzen

Info

Publication number
ATE154758T1
ATE154758T1 AT94929595T AT94929595T ATE154758T1 AT E154758 T1 ATE154758 T1 AT E154758T1 AT 94929595 T AT94929595 T AT 94929595T AT 94929595 T AT94929595 T AT 94929595T AT E154758 T1 ATE154758 T1 AT E154758T1
Authority
AT
Austria
Prior art keywords
pct
chronic pain
levobupivacain
useful
treating chronic
Prior art date
Application number
AT94929595T
Other languages
English (en)
Inventor
Hazel Judith Bardsley
Laurence Mather
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10743430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE154758(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Application granted granted Critical
Publication of ATE154758T1 publication Critical patent/ATE154758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
AT94929595T 1993-10-13 1994-10-13 Levobupivacain nützlich zur behandlung von chronischen schmerzen ATE154758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321061A GB9321061D0 (en) 1993-10-13 1993-10-13 Analgestic agent and its use

Publications (1)

Publication Number Publication Date
ATE154758T1 true ATE154758T1 (de) 1997-07-15

Family

ID=10743430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929595T ATE154758T1 (de) 1993-10-13 1994-10-13 Levobupivacain nützlich zur behandlung von chronischen schmerzen

Country Status (15)

Country Link
US (1) US5955479A (de)
EP (1) EP0723444B1 (de)
JP (1) JPH09503777A (de)
KR (1) KR100343314B1 (de)
CN (1) CN1074919C (de)
AT (1) ATE154758T1 (de)
AU (1) AU692477B2 (de)
CA (1) CA2173208C (de)
DE (1) DE69403969T2 (de)
DK (1) DK0723444T3 (de)
ES (1) ES2105766T3 (de)
GB (1) GB9321061D0 (de)
GR (1) GR3024787T3 (de)
NO (1) NO309304B1 (de)
WO (1) WO1995010276A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216583C (en) * 1995-04-13 2007-10-30 Chiroscience Limited Levobupivacaine and its use as an anaesthetic in pregnant women
GB9704352D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
GB9704370D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
DE69824730T2 (de) * 1997-07-21 2005-07-14 Levin, Bruce H. Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
ATE239474T1 (de) * 1997-07-22 2003-05-15 Darwin Discovery Ltd Verwendung von levobupivacain
US6045824A (en) 1997-09-18 2000-04-04 Skyepharma Inc. Sustained-release liposomal anesthetic compositions
AU752802C (en) 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
BR9814883A (pt) * 1997-11-19 2000-10-03 Darwin Discovery Ltd Formulação anestésica
WO2000003660A1 (en) 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
WO2002096368A2 (en) * 2001-05-31 2002-12-05 Skyepharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
AU2002359407B2 (en) 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004012703A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
DE102008037682A1 (de) * 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA3048485C (en) * 2016-12-26 2022-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12285419B2 (en) 2021-10-14 2025-04-29 Pacira Pharmaceuticals, Inc. Bupivacaine multivesicular liposome formulations and uses thereof
US12070454B1 (en) 2022-05-05 2024-08-27 Pfof Llc Anesthetic nerve block and method
CN119677554A (zh) 2022-05-05 2025-03-21 普络夫有限责任公司 麻醉神经阻滞和方法
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide
AU694453B2 (en) * 1993-10-13 1998-07-23 Darwin Discovery Limited Analgesic agent and its use
ITTO20010597A1 (it) * 2001-06-20 2002-12-20 Plaset Spa Pompa per liquidi, in particolare pompa centrifuga per apparecchi elettrodomestici.

Also Published As

Publication number Publication date
HK1006421A1 (en) 1999-02-26
NO309304B1 (no) 2001-01-15
WO1995010276A1 (en) 1995-04-20
DE69403969D1 (de) 1997-07-31
JPH09503777A (ja) 1997-04-15
DE69403969T2 (de) 1997-11-20
GR3024787T3 (en) 1998-01-30
NO961478L (no) 1996-06-11
NO961478D0 (no) 1996-04-12
AU7859394A (en) 1995-05-04
CN1133009A (zh) 1996-10-09
CN1074919C (zh) 2001-11-21
DK0723444T3 (da) 1997-12-29
ES2105766T3 (es) 1997-10-16
AU692477B2 (en) 1998-06-11
CA2173208C (en) 2007-01-30
EP0723444A1 (de) 1996-07-31
CA2173208A1 (en) 1995-04-20
GB9321061D0 (en) 1993-12-01
US5955479A (en) 1999-09-21
KR100343314B1 (ko) 2003-02-19
EP0723444B1 (de) 1997-06-25

Similar Documents

Publication Publication Date Title
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69228938D1 (de) Methode und zusammensetzungen zur behandlung von zerebralparalyse
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE69333014D1 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE69304843D1 (de) Methode zur Behandlung von Haarausfall
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
DE69630055D1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
DE69627298D1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EEIH Change in the person of patent owner